a 66

A66 is a specific and effective p110α inhibitor(IC50=32 nM).

SH-E4A-66 is a C2-COUPLr (COvalent Protein Ligators) featuring a carbazole skeleton, which does not include heterogeneous cysteine-reactive warheads such as acrylamide and chloroacetamide. This compound effectively couples with EML4-ALK (EC50=1.5 μM) and inhibits the kinase activity of EML4-ALK (IC50=2.3 µM).

Synta66 is a store-operated calcium entry channel Orai inhibitor, and used for the research of neurological disease.

DC_C66 DC_C66 has good selectivity for CARM1, PRMT1 (IC50 = 21μM), PRMT6 (IC50 = 47μM) and PRMT5. It is a cell-permeable, selective co-activator related arginine methyltransferase 1 (CARM1) inhibitor with IC50 of 1.8 μM.

MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.

Compound 143673-66-9, with CAS No. 143673-66-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 143673-66-9 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 132521-66-5, with CAS No. 132521-66-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 132521-66-5 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 15018-66-3, with CAS No. 15018-66-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 15018-66-3 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

NLRP3-IN-66 (example 257) is a potent inhibitor of the NLRP3 inflammasome.

Antiproliferative agent-66 (Compound B3) is an antiproliferative compound that induces apoptosis and causes cell cycle arrest. It demonstrates IC50 values ranging from 2.03 to 3.6 µM against SH-SY5Y neuroblastoma, HT-29 colorectal adenocarcinoma, and fibroblasts. Additionally, Antiproliferative agent-66 functions as a microtubule polymerization inhibitor with an IC50 of 0.79 µM.

E3ligaseLigand 66 is an E3 ligase ligand that facilitates the recruitment of IAP proteins. It can be linked with SARS-CoV-2 Mpro ligand 1 via a linker to form PROTACBP-198.

Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory properties. It inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice.

HDAC-IN-66 (compound 2F) is a selective inhibitor of HDAC and a derivative of Pomalidomide, effectively inhibiting hematological tumor cells.

E3ligaseLigand-Linker Conjugate 66 is a conjugate composed of an E3 ligase ligand and a linker, specifically formed from Thalidomide and its corresponding linker. It functions as a Cereblon ligand, recruiting the CRBN protein and serving as a crucial intermediate in the synthesis of complete PROTACs molecules.

NZ-66 is a chimeric molecule that targets UNC-51-like kinase 1 (ULK1) to facilitate proximity-induced, ULK1-dependent mitochondrial degradation. It triggers mitophagy (mitochondrial autophagy) and has potential for alleviating neurodegenerative diseases.

BAK2-66 is a selective antagonist of the dopamine D3 receptor.

Antitumor agent-66 (Compound 4) is a derivative of (-)-cleistenolide, exhibiting potential as a research tool for cancer diseases [1].

Antibacterial agent 66 (Compound 6q) is a trifluoromethylpyridine 1,3,4-oxadiazole derivative active against Xanthomonas oryzae pv. oryzae (Xoo) (EC50: 7.2 μg/mL).

ZLM-66 is a doravirine analogue and a potent inhibitor of non-nucleoside reverse transcriptases (NNRTIs), acting on wild-type HIV-1 reverse transcriptase (IC50: 41 nM), wild-type HIV-1 (EC50: 13 nM) and cIAP1 (EC50: 0.32 nM). ZLM-66 can be used in AIDS research.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

SARS-CoV-2-IN-66 (1), a derivative of vitamin K, serves as an inhibitor of SARS-CoV-2, with an effective concentration (EC50) of 70.8 μM in VeroE6/TMPRSS2 cells [1].

HSD17B13-IN-66 (Compound 146), an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), shows a potent IC 50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research pertaining to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1].

MB-66 (MAPP-66) is a fully human IgG1 antibody targeting HSV and HIV. It is a monoclonal antibody membrane intended for vaginal application. The isotype control for MB-66 can be referred to as HumanIgG1kappa, Isotype Control.

CEF1, Influenza Matrix Protein M1 (58-66), is an epitope derived from the matrix protein of the influenza A virus. GILGFVFTL is an HLA-A2-restricted epitope from this matrix M1 protein.